Lincoln, Nebraska, Oct. 24, 2023 (GLOBE NEWSWIRE) -- National Research Corporation (NASDAQ/:NRC) today announced that it will provide an online web simulcast of its 2023 third quarter earnings conference call on Wednesday, November 8, 2023. The Company’s results for the 2023 third quarter will be released after the close of the market on Tuesday, November 7, 2023.
The live broadcast of National Research Corporation’s conference call will begin at 11:00 a.m. Eastern Time on November 8, 2023. A 30-day online replay will be available approximately one hour following the conclusion of the live broadcast.
A live audio webcast can be accessed at https://events.q4inc.com/attendee/533804877. The webcast will also be available for replay.
For more than 40 years, NRC Health (NASDAQ: NRC) has led the charge to humanize healthcare and support organizations in their understanding of each unique individual. NRC Health’s commitment to Human Understanding® helps leading healthcare systems get to know each person they serve not as point-in-time insights, but as an ongoing relationship. Guided by its uniquely empathic heritage, NRC Health’s patient-focused approach, unmatched market research, and emphasis on consumer preferences are transforming the healthcare experience, creating strong outcomes for patients and entire healthcare systems. For more information, email This email address is being protected from spambots. You need JavaScript enabled to view it., or visit www.nrchealth.com.
Last Trade: | US$10.54 |
Daily Change: | 0.01 0.09 |
Daily Volume: | 80,500 |
Market Cap: | US$247.480M |
February 25, 2025 January 27, 2025 October 25, 2024 August 22, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load